Mobilizing Innovation for Rapid Testing
As the pandemic surged, GBC rose to the challenge. Partnering with a major medical university, the company developed rapid COVID-19 test kits and implemented automated, high-throughput screening systems capable of processing up to 1,440 samples a day—ensuring swift identification and response during critical moments in epidemic control.
Sustained Diagnostic Performance
GBC’s diagnostic portfolio—including RT-PCR nucleic acid tests, antigen rapid kits, ELISA antibody tests, viral transport media, and extraction reagents—delivered over 90% accuracy across key variants, such as Alpha through Omicron. This reaffirmed GBC’s role in ensuring reliable diagnostics amid changing viral landscapes.
Strengthening Local Community Screening
At a time when national testing capacity was strained, GBC donated 20,000 RT-PCR test reagents to Hsinchu County and City. Simultaneously, the company engaged with municipal health authorities and hospitals to support the rapid establishment of community testing stations, strengthening grassroots epidemic surveillance and resilience.
Extending a Hand Globally
GBC also joined hands with a major foundation to donate 850 ELISA antibody test kits (enough to test over 81,600 individuals) to a friendly partner nation, demonstrating international solidarity. The Ministry of Foreign Affairs facilitated distribution, reinforcing how private, public, and philanthropic sectors can unite in global health crises.
Why it matters
• Innovation at scale: Demonstrated capability to respond to surging testing demands rapidly and accurately.
• Public health ally: Supported both local communities and international partners—highlighting GBC’s holistic approach to social responsibility.
• Resilience through partnership: Collaborative efforts across academia, government, NGOs, and health authorities underscore the impact of cross-sector action.
As the pandemic surged, GBC rose to the challenge. Partnering with a major medical university, the company developed rapid COVID-19 test kits and implemented automated, high-throughput screening systems capable of processing up to 1,440 samples a day—ensuring swift identification and response during critical moments in epidemic control.
Sustained Diagnostic Performance
GBC’s diagnostic portfolio—including RT-PCR nucleic acid tests, antigen rapid kits, ELISA antibody tests, viral transport media, and extraction reagents—delivered over 90% accuracy across key variants, such as Alpha through Omicron. This reaffirmed GBC’s role in ensuring reliable diagnostics amid changing viral landscapes.
Strengthening Local Community Screening
At a time when national testing capacity was strained, GBC donated 20,000 RT-PCR test reagents to Hsinchu County and City. Simultaneously, the company engaged with municipal health authorities and hospitals to support the rapid establishment of community testing stations, strengthening grassroots epidemic surveillance and resilience.
Extending a Hand Globally
GBC also joined hands with a major foundation to donate 850 ELISA antibody test kits (enough to test over 81,600 individuals) to a friendly partner nation, demonstrating international solidarity. The Ministry of Foreign Affairs facilitated distribution, reinforcing how private, public, and philanthropic sectors can unite in global health crises.
Why it matters
• Innovation at scale: Demonstrated capability to respond to surging testing demands rapidly and accurately.
• Public health ally: Supported both local communities and international partners—highlighting GBC’s holistic approach to social responsibility.
• Resilience through partnership: Collaborative efforts across academia, government, NGOs, and health authorities underscore the impact of cross-sector action.
){kind=link}